[{"orgOrder":0,"company":"Pharma Two B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Undisclosed"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Termination","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Undisclosed"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Undisclosed"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Myung In Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Myung In Pharm"},{"orgOrder":0,"company":"Chongqing Fortune Pharmaceutical","sponsor":"Beijing Bionovo Medicine Development","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Chongqing Fortune Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chongqing Fortune Pharmaceutical \/ Beijing Bionovo Medicine Development","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Fortune Pharmaceutical \/ Beijing Bionovo Medicine Development"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"H. Lundbeck AS | CHU Purpan | H\u00f4pital Haut-L\u00e9v\u00eaque | Centre Hospitalier de la c\u00f4te Basque | Poitiers University Hospital | CHU de Rennes | University Hospital, Lille | H\u00f4pital Dupuytren | University Hospital, Caen | Centre Hospitalier Universitaire de N\u00eem","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ H. Lundbeck AS | CHU Purpan | H\u00f4pital Haut-L\u00e9v\u00eaque | Centre Hospitalier de la c\u00f4te Basque | Poitiers University Hospital | CHU de Rennes | University Hospital, Lille | H\u00f4pital Dupuytren | University Hospital, Caen | Centre Hospitalier Universitaire de N\u00eem","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Clermont-Ferrand \/ H. Lundbeck AS | CHU Purpan | H\u00f4pital Haut-L\u00e9v\u00eaque | Centre Hospitalier de la c\u00f4te Basque | Poitiers University Hospital | CHU de Rennes | University Hospital, Lille | H\u00f4pital Dupuytren | University Hospital, Caen | Centre Hospitalier Universitaire de N\u00eem"},{"orgOrder":0,"company":"Qualissima","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"Qualissima","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualissima \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"Qualissima \/ H. Lundbeck AS"},{"orgOrder":0,"company":"University of Zurich","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Zurich \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"University of Zurich \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Technische Universit\u00e4t Dresden","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Sleep","graph2":"Phase IV","graph3":"Technische Universit\u00e4t Dresden","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technische Universit\u00e4t Dresden \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Technische Universit\u00e4t Dresden \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Bial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase I","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bial \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bial \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharmaceutical Industries \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgetown University \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Georgetown University \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Brown University","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Brown University \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Virginia \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"9","companyTruncated":"University of Virginia \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Yunxia Wang, MD","sponsor":"Western ALS Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase II","graph3":"Yunxia Wang, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yunxia Wang, MD \/ Western ALS Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Yunxia Wang, MD \/ Western ALS Study Group"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Prof. Dr. Stefan Lorenzl","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Prof. Dr. Stefan Lorenzl","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Prof. Dr. Stefan Lorenzl"}]
Find Clinical Drug Pipeline Developments & Deals for Rasagiline
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
